FDA Approves Roche's Oral Breast Cancer Therapy Wilserdly
Roche (RHHBF) has received FDA approval for its new oral breast cancer therapy, Wilserdly (giredestrant). This regulatory milestone represents the first of two expected U.S. decisions regarding this specific treatment within the current year. The approval marks a significant step in Roche's oncology portfolio, providing a new oral option for patients battling certain types of breast cancer. Market observers will be watching for further regulatory developments and subsequent commercial rollout strategies.